Home » Stocks » Mallinckrodt

Mallinckrodt PLC (MNK)

Stock Price: $1.40 USD -0.10 (-6.67%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
After-hours: $1.41 +0.01 (0.71%) Aug 11, 7:59 PM

Stock Price Chart

Key Info

Market Cap 118.42M
Revenue (ttm) 2.38B
Net Income (ttm) -2.14B
Shares Out 84.46M
EPS (ttm) -25.44
PE Ratio n/a
Forward PE 0.45
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $1.40
Previous Close $1.50
Change ($) -0.10
Change (%) -6.67%
Day's Open 1.52
Day's Range 1.38 - 1.53
Day's Volume 5,705,850
52-Week Range 1.00 - 6.42

More Stats

Market Cap 118.42M
Enterprise Value 4.54B
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 84.46M
Float 83.65M
EPS (basic) -25.45
EPS (diluted) -25.44
FCF / Share 4.89
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 349.08%
Payout Ratio n/a
Shares Short 41.75M
Short Ratio 11.95
Short % of Float 50.19%
Beta 3.29
PE Ratio n/a
Forward PE 0.45
P/FCF Ratio 0.29
PS Ratio 0.05
PB Ratio 0.13
Revenue 2.38B
Operating Income -2.54B
Net Income -2.14B
Free Cash Flow 413.40M
Net Cash -4.42B
Net Cash / Share -52.31
Gross Margin 60.12%
Operating Margin -106.66%
Profit Margin -89.90%
FCF Margin 17.36%
ROA -2.36%
ROE -107.26%
ROIC -31.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 0
Overweight 0
Hold 7
Underweight 1
Sell 3

Analyst Consensus: Hold

Price Target

$1.78*
(27.14% upside)
Low
1.00
Current: $1.40
High
3.00
Target: 1.78
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue3,1633,2163,2223,3812,9231,6501,7122,0562,0222,048
Revenue Growth-1.65%-0.19%-4.71%15.66%77.13%-3.62%-16.73%1.7%-1.26%-
Gross Profit1,4211,4711,6581,8581,623885822965915932
Operating Income-1,822-3,72149363335443.4073.50235241237
Net Income-997-3,6072,134644325-31958.80135151201
Shares Outstanding83.9084.0097.7011111664.9057.7057.7057.70-
Earnings Per Share-11.88-42.9421.805.772.75-4.921.022.332.61-
EPS Growth--277.82%109.82%---56.22%-10.73%--
Operating Cash Flow7436667271,185931373136256370402
Capital Expenditures-133-127-186-183-148-128-148-144-120-104
Free Cash Flow6105395411,002783246-12.00112250299
Cash & Equivalents7913491,4152813667082760.000.000.00
Total Debt5,3756,0926,7356,0456,4963,89592010.2011.70-
Net Cash / Debt-4,584-5,743-5,320-5,765-6,130-3,187-644-10.20-11.700.00
Assets10,33910,87715,28115,49916,40412,7873,5572,8992,823-
Liabilities8,3987,9908,75910,22811,0937,8292,3011,0071,035-
Book Value1,9412,8876,5225,2715,3114,9581,2561,8921,789-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Mallinckrodt PLC
Country Ireland
Employees 3,400
CEO Mark C. Trudeau

Stock Information

Ticker Symbol MNK
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drugs - Generic
Unique Identifier NYSE: MNK

Description

Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers Acthar Gel, an injectable drug for rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; and Therakos photopheresis, an immunotherapy treatment platform, as well as Amitiza, a product for constipation. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; and SLN500, a ribonucleic acid technology therapy. It markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc. The company was founded in 1867 and is based in Staines-Upon-Thames, the United Kingdom.